![]() |
Name |
1-acetyl-β-carboline
|
Molecular Formula | C13H10N2O | |
IUPAC Name* |
1-(9H-pyrido[3,4-b]indol-1-yl)ethanone
|
|
SMILES |
CC(=O)c1nccc2c1[nH]c1ccccc12
|
|
InChI |
InChI=1S/C13H10N2O/c1-8(16)12-13-10(6-7-14-12)9-4-2-3-5-11(9)15-13/h2-7,15H,1H3
|
|
InChIKey |
NXZSUJKPVSDFNF-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 210.24 | ALogp: | 2.9 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 45.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.622 |
Caco-2 Permeability: | -4.88 | MDCK Permeability: | 0.00001810 |
Pgp-inhibitor: | 0.013 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.074 |
30% Bioavailability (F30%): | 0.054 |
Blood-Brain-Barrier Penetration (BBB): | 0.896 | Plasma Protein Binding (PPB): | 83.50% |
Volume Distribution (VD): | 1.183 | Fu: | 11.92% |
CYP1A2-inhibitor: | 0.992 | CYP1A2-substrate: | 0.856 |
CYP2C19-inhibitor: | 0.712 | CYP2C19-substrate: | 0.271 |
CYP2C9-inhibitor: | 0.33 | CYP2C9-substrate: | 0.87 |
CYP2D6-inhibitor: | 0.699 | CYP2D6-substrate: | 0.729 |
CYP3A4-inhibitor: | 0.574 | CYP3A4-substrate: | 0.235 |
Clearance (CL): | 3.323 | Half-life (T1/2): | 0.403 |
hERG Blockers: | 0.024 | Human Hepatotoxicity (H-HT): | 0.898 |
Drug-inuced Liver Injury (DILI): | 0.968 | AMES Toxicity: | 0.474 |
Rat Oral Acute Toxicity: | 0.974 | Maximum Recommended Daily Dose: | 0.791 |
Skin Sensitization: | 0.78 | Carcinogencity: | 0.395 |
Eye Corrosion: | 0.087 | Eye Irritation: | 0.982 |
Respiratory Toxicity: | 0.987 |